Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
3. august 2012 oppdatert av: Ingrid Mayer, MD, Vanderbilt-Ingram Cancer Center
A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with erlotinib may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying how well giving letrozole together with erlotinib works in treating postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally recurrent or metastatic breast cancer.
Studieoversikt
Status
Avsluttet
Forhold
Detaljert beskrivelse
OBJECTIVES:
Primary
- To determine the rate of clinical benefit (complete response [CR], partial response [PR], and stable disease [SD] in patients with hormone-dependent locally recurrent or metastatic breast cancer treated with letrozole in combination with erlotinib hydrochloride.
Secondary
- To determine the time to progression (TTP) in patients treated with this regimen.
- To evaluate the anti-tumor activity, as determined by CR and PR rates, of this regimen in these patients.
- To evaluate the safety of this regimen in these patients.
- To determine if tumors that are positive for epidermal growth factor receptor (EGFR) or Ser118 ER, or that overexpress human epidermal receptor (HER2) exhibit a longer TTP from the combination compared to tumors that do not express or overexpress these molecules.
OUTLINE: This is a multicenter study. Patients are stratified according to prior hormone therapy (hormone-therapy naive/first-line therapy vs prior hormonal therapy with either tamoxifen or an aromatase inhibitor in the adjuvant or metastatic setting/second-line therapy)
Patients receive oral letrozole and oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.
Studietype
Intervensjonell
Registrering (Faktiske)
48
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Georgia
-
Macon, Georgia, Forente stater, 31201
- Central Georgia Hematology/Oncology Associates, P.C.
-
-
Kentucky
-
Hopkinsville, Kentucky, Forente stater, 42240
- Jennie Stuart Medical Center
-
Paducah, Kentucky, Forente stater, 42002
- Purchase Cancer Group
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- Memorial Health Care System
-
Germantown, Tennessee, Forente stater, 38138
- The Jones Clinic - Germantown
-
Jackson, Tennessee, Forente stater, 38301
- Jackson-Madison County Hospital
-
Knoxville, Tennessee, Forente stater, 37909
- Tennessee Cancer Specialists
-
Nashville, Tennessee, Forente stater, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Forente stater, 37067
- Vanderbilt-Ingram Cancer Center - Cool Springs
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
- Patients must have estrogen (ER) and/or progesterone receptor (PgR)-positive, histologically confirmed adenocarcinoma of the breast with measurable (but not operable) locally recurrent disease, or measurable and/or evaluable metastatic disease (see protocol section 10.3), including isolated bone metastases.
- Patients with available paraffin tissue blocks from either the primary or the metastatic site must submit tissue blocks for retrospective EGFR and HER2 analysis. If tissue blocks cannot be submitted, 20 unstained slides from each paraffin block must be submitted.
All patients must be post-menopausal females as defined by one of the following:
- Prior bilateral oophorectomy
- Prior bilateral ovarian irradiation
- No menstrual period for 12 months or longer
- If age 55 years or less and < 12 months from last menstrual period, patient must have a serum estradiol < or equal to 30 and an FSH level > 40.
- Patients must not have had more than 1 prior chemotherapy regimen for metastatic disease and have fully recovered from any grade 2-4 toxicities related to chemotherapy. No concurrent chemotherapy is allowed while on protocol therapy.
- Patients may have had 1 prior hormonal therapy for metastatic disease. This includes: tamoxifen, fulvestrant, anastrozole, exemestane, aminoglutethimide, megace, and letrozole. Patients may have received tamoxifen or aromatase inhibitors in the adjuvant setting.
- Patients must not have had prior therapy with EGF receptor inhibitors.
- Previous but not concomitant therapy with trastuzumab (Herceptin) is allowed. Patients must not have received Herceptin within 4 weeks of initiation of protocol therapy.
- Patients must have an ECOG performance status of 0, 1, or 2.
Patients must have adequate hematologic, hepatic, and renal function as defined by the following within 2 weeks of initiation of therapy:
- Absolute neutrophils > or equal to 1,500/mm3 and platelets > or equal to 100,000/mm3.
- Bilirubin < than or equal to 1.5 upper limit of normal.
- SGOT and SGPT < or equal to 2.5 upper limit of normal.
- Creatinine < or equal to 1.5 upper limit of normal.
- INR, PTT and PT in the normal range.
- Must be 18 years of age or older.
- Patients must not have a history of central nervous system metastases or unevaluated CNS symptoms suggestive of possible brain metastases.
- Patients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry and sites of evaluable disease outside the radiation port(s) are available for follow-up. Patients who have received prior radiotherapy must have recovered from toxicity induced by this treatment.
- Patients < 55 years of age must not have received Luteinizing hormone releasing hormone (LHRH) antagonists within 3 months prior to protocol therapy.
- Patients must not suffer from medical or psychiatric conditions that would interfere with ability to provide informed consent, communicate side effects, or comply with protocol requirements including maintenance of a compliance/pill diary.
- Patients must be disease-free of prior invasive cancers for > 5 years with the exception of basal or squamous cancer of the skin or cervical carcinoma in situ.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: First line/hormone-therapy naive
|
OSI-774 150 mg/day
Andre navn:
Letrozole 2.5 mg/day
Andre navn:
To determine HER2 gene amplification or excess copies of the HER2 gene
Andre navn:
to measure the epidermal growth factor receptors (EGFR)
Andre navn:
To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Andre navn:
|
|
Eksperimentell: Second-line/prev hormone-therapy tx
|
OSI-774 150 mg/day
Andre navn:
Letrozole 2.5 mg/day
Andre navn:
To determine HER2 gene amplification or excess copies of the HER2 gene
Andre navn:
to measure the epidermal growth factor receptors (EGFR)
Andre navn:
To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Patients With Pathological Complete Response.
Tidsramme: at 24 weeks
|
Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions
|
at 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Median Time to Progression of Target Lesions
Tidsramme: Every 12 weeks from on-study to disease progression
|
Time frame from study entry till discontinuation of treatment due to disease progression.
Progression of target lesions is measured by RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions.
|
Every 12 weeks from on-study to disease progression
|
|
Number of Patients With Anti-tumor Activity: Complete Response (CR) and Partial Response (PR)
Tidsramme: at 24 weeks
|
Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions and partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions.
|
at 24 weeks
|
|
Number of Patients With Worst-grade Toxicities Per Grade
Tidsramme: at 24 weeks
|
Number of patients with worst-grade toxicities following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death
|
at 24 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. november 2003
Primær fullføring (Faktiske)
1. desember 2008
Studiet fullført (Faktiske)
1. desember 2008
Datoer for studieregistrering
Først innsendt
8. februar 2008
Først innsendt som oppfylte QC-kriteriene
8. februar 2008
Først lagt ut (Anslag)
11. februar 2008
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
9. august 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. august 2012
Sist bekreftet
1. august 2012
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Neoplasmer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Brystneoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Hormoner, hormonsubstitutter og hormonantagonister
- Proteinkinasehemmere
- Hormonantagonister
- Aromatasehemmere
- Steroidesyntesehemmere
- Østrogenantagonister
- Erlotinib hydroklorid
- Letrozol
Andre studie-ID-numre
- VICC BRE 0303
- VU-VICC-BRE-0303
- VU-VICC-030592
- GENENTECH-VU-VICC-BRE-0303
- NOVARTIS-VU-VICC-BRE-0303
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .